公开(公告)号：US20230132790A1

公开(公告)日：2023-05-04

申请号：US17915500

申请日：2021-03-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Anthony H. FUTERMAN ,  Israel SILMAN ,  Joel L. SUSSMAN ,  Sarel FLEISHMAN ,  Adi GOLDENZWEIG ,  Sarka POKORNA ,  Yaacov ASHANI ,  Olga KHERSONSKY

IPC: C12N9/24

Abstract: A genetically modified human beta-glucocerebrosidase (GCase) is disclosed. The genetically modified GCase comprising an amino acid sequence at least 85% identical to SEQ ID NO: 2; and comprising mutations at coordinates L34P, K224N/G, T369E and N370D, where the coordinates correspond to said SEQ ID NO: 2; and capable of catalyzing hydrolysis of a glycolipid glucosylceramide (GlcCer). Pharmaceutical compositions comprising the genetically modified GCase and therapeutic methods of using same are also disclosed.

公开(公告)号：US20210275473A1

公开(公告)日：2021-09-09

申请号：US17261255

申请日：2019-07-17

Applicant: Yeda Research and Development Co. Ltd. ,  University of Duisburg-Essen

Inventor： Anthony H. FUTERMAN ,  Tammar JOSEPH ,  Walter A. SHAW ,  Stephen W. BURGESS ,  Shengrong LI

IPC: A61K31/167 ,  A61K31/133 ,  A61K31/164

Abstract: Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.